XML 58 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Disaggregation Of Revenue [Line Items]      
Sources of revenue, description We derive our revenue from two sources: (i) Diagnostic Tests, providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Development Services, providing diagnostic testing services to biopharmaceutical, life sciences, and diagnostic companies.    
Revenue recognized $ 500    
Deferred revenue $ 788   $ 678
Revenue | Minimum | Customer Concentration Risk | Medicare      
Disaggregation Of Revenue [Line Items]      
Concentration risk, percentage 36.00% 40.00%  
Up Front Cash Payments      
Disaggregation Of Revenue [Line Items]      
Deferred revenue $ 400    
Other Long-term Liabilities      
Disaggregation Of Revenue [Line Items]      
Non-current deferred revenue $ 200   $ 200